NPC1L1 and ovarian carcinoma: [126] performed a genome‐wide association study (GWAS) meta‐analysis and found that in breast invasive carcinoma (BRCA) 1/2 gene mutation carriers, HMG‐CoA reductase inhibition was associated with a lower risk of ovarian cancer, while NPC1L1 and circulating LDL cholesterol inhibition were not significantly associated with epithelial ovarian cancer.